Psychotropic Drug Use in Israel

Grinshpoon, Alexander; Marom, Eli; Weizman, Abraham; Ponizovsky, Alexander M.

doi:10.4088/pcc.v09n0504

Cited by 16 publications

(14 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The prevalent use of psychotropic medications assessed in this investigation by community dwelling elderly aged 75–94 (24%–28%) is in line with other findings from Israel (Grinshpoon et al, 2007) for elderly aged 70 and over (23%) but higher than reported for ages 65 and over in the U.S. (19%) for all psychotropic prescriptions (Aparasu, Mort, & Brandt, 2003). …”

Section: Discussionsupporting

confidence: 90%

“…Similar findings were observed in The Netherlands where a decreased risk of ADHD medications was shown among Turkish and Moroccan immigrants as compared to the native population (Wittkampf et al, 2010). Lower use of psychotropic medications by Orthodox Jews was also observed in the former mentioned Israeli national study which pointed to the negative attitudes of Orthodox Jews to mental disorders (Grinshpoon et al, 2007). …”

Section: Discussionmentioning

confidence: 70%

“…Findings with regard to age are less consistent. In several community studies, use of benzodiazepines increased among those 85 years and older (Morgan, Dallosso, Ebrahim, Arie, & Fentem, 1988; Stewart, Marks, Padgett, & Hale, 1994) while in another survey it increased after the age of 75 (Dealberto et al, 1997) and after the age of 70 in Israel (Grinshpoon, Marom, Weizman, & Ponizovsky, 2007). The last mentioned population-based study that assessed the use of psychotropic medications in Israel did not estimate trends over time.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence and correlates of psychotropic medication use among older adults in Israel: Cross-sectional and longitudinal findings from two cohorts a decade apart

Blumstein

Benyamini

Chetrit

et al. 2012

Aging & Mental Health

View full text Add to dashboard Cite

Objectives To assess: 1) changes in use of psychotropic medications across two cohorts, ten years apart, of community-dwelling elderly and the socio-demographic, physical and mental health correlates of their use; and 2) changes in psychotropic medication use over 3.5 years follow-up. Methods Data were taken from two national surveys of the Israeli Jewish population aged 75–94, which respectively sampled two cohorts in 1989 (n=1200) and again in 1999 (n=421). Psychotropic medications were assessed from the list of all medications recorded during a face-to-face interview. The current analysis focused on two medication groups: anxiolytics & sedatives/hypnotics and antidepressants. Results Sedatives/hypnotics & anxiolytics use increased from 22.2% in 1989 to 25.4% in 1999 and antidepressants from 3.8% to 4.8% (both nonsignificantly) corresponding to a decline in the health profile of community-dwelling older adults. Similar patterns of associations were observed for socio-demographics, physical and mental health status indicators with use of psychotropic medications across the two cohorts. The pooled multivariate analysis showed significantly higher use of sedative/hypnotics & anxiolytics among women and lower use among religious elderly. Additional risk factors were sleeping problems, number of other medications, depressive symptoms and traumatic life events. Antidepressants use was related to a higher education, ADL disability and depressive symptoms. Longitudinally, use of psychotropic medications was not significantly different among participants who were followed again after 3.5 years. Conclusions Sedative/hypnotics & anxiolytics use was relatively high while antidepressants use was low even among depressed elderly suggesting that some depressed elderly were treated inappropriately with benzodiazepines.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 70%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and correlates of psychotropic medication use among older adults in Israel: Cross-sectional and longitudinal findings from two cohorts a decade apart

Blumstein

Benyamini

Chetrit

et al. 2012

Aging & Mental Health

View full text Add to dashboard Cite

show abstract

“…The prevalence of overall drug consumption in São Paulo in the 70s was 12.9% [ 4 ], decreasing to 10.6% in the 80s [ 1 ], 7% [ 5 ] in 2002 and then to 8.8% in 2007. Comparing to results from the WHO World Mental Health Surveys vary from, our rates are similar in Spain (16%) [ 35 ], lower than France (21%) [ 36 ], Belgium (19%) [ 37 ], but higher than Israel (7%) [ 38 ], Canada (7%) [ 39 ] and Germany (6%) [ 13 ].…”

Section: Discussionmentioning

confidence: 68%

Psychotropic Drug Use in São Paulo, Brazil – An Epidemiological Survey

et al. 2015

View full text Add to dashboard Cite

ObjectiveTo estimate the prevalence of one month psychotropic drug use in São Paulo, Brazil, and to assess the gap treatment between the presence of mental disorders and psychotropic drug users.MethodA probabilistic sample of non-institutionalized individuals from the general population of São Paulo (n = 2336; turnout: 84.5%) who were 15 years or older were interviewed by a trained research staff, applying the Composite International Diagnostic Interview 2.1 (CIDI WHO) (depression, anxiety-phobia, OCD\PTSD, alcoholism sections), and an inventory investigating psychotropic drug use during the 12-month and one-month periods immediately preceding the interview. Logistic models were fitted to investigate associations between psychotropic drug use as well as socio-demographic and clinical variables.ResultsThe one month prevalence of psychotropic drug use in São Paulo was 5.89%, the most commonly used drugs were antidepressants (3.15%) and tranquilizers (2.67%). A higher consumption of psychotropic drugs (overall, antidepressants and tranquilizers) was observed among women (OR:2.42), older individuals (OR:1.04), individuals with higher levels of formal education (1.06), and individuals with a family (OR:2.29) or personal history of mental illness (OR:3.27). The main psychotropic drug prescribers were psychiatrists (41%), followed by general practitioners (30%); 60% of psychotropic drugs were obtained through a government-run dispensing program. Most individuals who obtained a positive diagnosis on the CIDI 2.1 during the previous month were not using psychotropic medication (85%). Among individuals with a diagnosis of moderate to severe depression, 67.5% were not on any pharmacological treatment.ConclusionThere is a change in the type of psychotropic more often used in São Paulo, from benzodiazepines to antidepressants, this event is observed in different cultures. The prevalence of use is similar to other developing countries. Most of the patients presenting a psychiatric illness in the month prior to testing were not receiving any sort of psychiatric medication. This may be explained by a failure to identify cases in primary care, which could be improved (and access to treatment could be facilitated) if professionals received more specialized training in managing cases with mental health problems.

show abstract

“…In a series of pharmacoepidemiological studies conducted by the World Mental Health Survey Initiative (WMHS) ( 16 , 17 ), the use of psychotropic agents was evaluated in the general population. In addition, if a respondent had been diagnosed with a psychiatric disorder in the 12 months preceding the survey, this was recorded ( 18 , 19 ). The observed prevalence of BZD use in the general population ranged between 3.2% and 18.6% ( Table 1 ).…”

Section: Introductionmentioning

confidence: 99%

Benzodiazepine use in Sao Paulo, Brazil

Campanha¹,

Ravagnani²,

Milhorança³

et al. 2020

Clinics

View full text Add to dashboard Cite

OBJECTIVES: To report the prevalence and factors associated with the use of benzodiazepines in the general population and those with a mental health condition in the metropolitan area of São Paulo, Brazil. METHODS: 5,037 individuals from the Sao Paulo Megacity Mental Health Survey data were interviewed using the Composite International Diagnostic Interview, designed to generate DSM-IV diagnoses. Additionally, participants were asked if they had taken any medication in the previous 12 months for the treatment of any mental health condition. RESULTS: The prevalence of benzodiazepine use ranged from 3.6% in the general population to 7.8% among subjects with a mental health condition. Benzodiazepine use was more prevalent in subjects that had been diagnosed with a mood disorder as opposed to an anxiety disorder (14.7% vs. 8.1%, respectively). Subjects that had been diagnosed with a panic disorder (33.7%) or bipolar I/II (23.3%) reported the highest use. Individuals aged ≥50 years (11.1%), those with two or more disorders (11.2%), those with moderate or severe disorders (10%), and those that used psychiatric services (29.8%) also reported higher use. CONCLUSION: These findings give an overview of the use of benzodiazepines in the general population, which will be useful in the public health domain. Benzodiazepine use was higher in those with a mental health condition, with people that had a mood disorder being the most vulnerable. Furthermore, females and the elderly had high benzodiazepine use, so careful management in these groups is required.

show abstract

Psychotropic Drug Use in Israel

Abstract: Similar to findings in other European countries, our findings suggest that the majority of individuals diagnosed with a common mental disorder are not being treated with psychotropic drugs or are being inappropriately treated.

Cited by 16 publications

References 50 publications

Prevalence and correlates of psychotropic medication use among older adults in Israel: Cross-sectional and longitudinal findings from two cohorts a decade apart

Prevalence and correlates of psychotropic medication use among older adults in Israel: Cross-sectional and longitudinal findings from two cohorts a decade apart

Psychotropic Drug Use in São Paulo, Brazil – An Epidemiological Survey

Benzodiazepine use in Sao Paulo, Brazil

Contact Info

Product

Resources

About